HLA-G and hereditary clear cell renal cell carcinoma: However, patients who are mAb 4H84pos but lack the α3 domain—including those expressing HLA-G3, HLA-G4, and HLA-G7 isoforms—may not benefit from such immunotherapies In this regard, the first completed clinical trial (NCT04991740) involved 39 heavily pretreated patients with colorectal, ovarian, and renal cell carcinomas who received the CD3/HLA-G bispecific antibody JNJ-78306358 (21, 47).